Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Short term Debt (2020 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Short term Debt for 6 consecutive years, with $8.8 million as the latest value for Q4 2025.

  • Quarterly Short term Debt changed N/A to $8.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at $8.8 million for FY2025, N/A changed from the prior year.
  • Short term Debt hit $8.8 million in Q4 2025 for Eton Pharmaceuticals, up from $2.8 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $8.8 million in Q4 2025 to a low of $364000.0 in Q2 2022.
  • Historically, Short term Debt has averaged $2.6 million across 5 years, with a median of $1.5 million in 2023.
  • Biggest five-year swings in Short term Debt: crashed 51.4% in 2022 and later soared 420.81% in 2023.
  • Year by year, Short term Debt stood at $1.4 million in 2021, then decreased by 27.15% to $1.0 million in 2022, then skyrocketed by 420.81% to $5.4 million in 2023, then dropped by 23.33% to $4.1 million in 2024, then skyrocketed by 113.07% to $8.8 million in 2025.
  • Business Quant data shows Short term Debt for ETON at $8.8 million in Q4 2025, $2.8 million in Q3 2025, and $2.8 million in Q2 2025.